Do New Protease Inhibitors Offer Improved Clinical Effectiveness? Issues of PI Potency and Efficacy

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue SUPPL. 1, 2004, Pages

  Young, Benjamin ^a,c   Markowitz, Martin ^b  

^a ROSE MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c Denver ID Consultants   (United States)

Author keywords

AIDS; Antiretroviral therapy; Atazanavir; Clinical trial overview; Fosamprenavir; HIV infection; Protease inhibitors

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; DARUNAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; MACROLIDE; NELFINAVIR; ORAL CONTRACEPTIVE AGENT; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; UNCLASSIFIED DRUG; WARFARIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIARRHEA; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IN VITRO STUDY; INFECTION RISK; JAUNDICE; LIVER TOXICITY; LONG TERM CARE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SEX DIFFERENCE; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS ISOLATION; VIRUS LOAD;

EID: 1842433833     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338(13):853-860.
2. Palella F, Chmiel F, Deloria-Knoll M, et al., and the HOPS Investigators. Continued low mortality and morbidity, and HAART utilization among HIV-infected patients in the HIV Outpatient Study (HOPS) [abstract 268B]. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; Chicago, February 4-8, 2001.
3. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288(2):222-235.
4. U.S. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Washington, DC: U.S. Department of Health and Human Services, 2003.
5. Pozniak A, Gazzard B, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med. 2003;4(Suppl 1):1-41.
6. Gulick RM, Mellors JW, Havlir D, et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA. 1998;280(1):35-41.
7. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med. 1999;341(25):1865-1873.
8. Fischl M, Ribaudo H, Collier AC, et al. A randomized trail comparing 2 4-drug antiretroviral regimens with a 3-drug regimen in advanced HIV disease [abstract 41]. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; Seattle, February 24-28, 2002.
9. d'Arminio-Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.C.O.N.A. Study Group. Italian Cohort of Antiretroviral-Naive Patients. AIDS. 2000;14(5):499-507.
10. Acosta EP. Pharmacokinetic enhancement of protease inhibitors. J Acquir Immune Defic Syndr. 2002;29(Suppl)1:S11-S18.
11. Naderer O, Parks D, Rogers M, et al. Comparison of QD protease inhibitors (PIs): estimated Cmin/IC50 (IQ) after missed dose shows Agenerase advantage [abstract 352]. In: Abstracts of the 1st IAS Conference on HIV Pathogenesis and Treatment; Buenos Aires, Argentina, July 8-11, 2001.
12. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS. 2003;17(6):831-840.
13. McComsey GA, Chu A. Effect of ritonavir-boosted protease inhibitor (PI) regimens on lipid profiles [abstract ThPeB7319]. In: Abstracts of the XIV International AIDS Conference; Barcelona, July 7-12, 2002.
14. Piliero PJ, Cahn P, Pantaleo G, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile-results of clinical trials at week 48 [poster 706-T]. Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, February 22-28, 2002.
15. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32(1):18-29.
16. Squires KE, Thiry A, Giordano M, et al. Atazanavir (ATV) QD vs efavirenz (EFV) QD with fixed-dose zidovudine (ZDV) and lamivudine (3TC) BID: comparison of antiviral efficacy and safety 48-week results from BMS AI42-034 phase III Pivotal study [poster H-1026]. Presented at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002.
17. Sax PE. Do new protease inhibitors offer improved management options? issues of PI tolerability and safety. J Acquir Immune Defic Syndr. 2004;35(Suppl 1):S22-S34.
18. Nieto-Cisneros L, Zala C, Fessel WJ, et al. Antiviral efficacy, metabolic changes and safety of atazanavir (TAV) versus lipinavir/ritonavir (LPV/RTV) in combination with two NRTIs in patients who have experienced virologic failure with prior PI-containing regimen(s): 24 week results from BMS A1424-043 [abstract 117]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris: July 13-16, 2003.
19. Food and Drug Administration. Atazanavir Advisory Committee Briefing Document. Rockville, MD: Food and Drug Administration, Center for Drug Evaluation, 2003.
20. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) or saquinavir (SQV) versus lopinavir/ritonavir (LPV/RTV) in combination with tenofovir (TFV) and ione NRTI in patients who have experienced virologic failure to multiple HAART regimens: 16-week results from BMS AI424-045 [abstract 118]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
21. Reyataz prescribing information. Princeton, NJ: Bristol-Myers Squibb Virology, June 2003.
22. Lexiva prescribing information. Research Triangle Park, NC: GlaxoSmithKline, October 2003.
23. Falcoz C, Jenkins JM, Bye C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002;42(8):887-898.
24. Rodriguez-French A, Boghossian J, Gray GE, et al. The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients. J Acquir Immune Defic Syndr. 2004;35:22-32.
25. Schürmann D, Gathe J, Sanne I, et al. Efficacy and safety of GW433908/ritonavir once daily in therapy-naive subjects, 48 week results: the SOLO Study [abstract PL 14.4]. In: Abstracts of the Sixth International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland, November 17-21, 2002.
26. De Jesus E, LaMarca A, Sension M, et al. The Context Study: efficacy and safety of GW433908/RTV in PI-experienced subjects with virological failure (24 week results) [abstract 178]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
27. Yu D, Suzuki M, Xie L, et al. Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev. 2003;23(3):322-345.
28. Thaisrivongs S, Strohbach JW. Structure-based discovery of tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor. Biopoly. 1999;51:51-58.
29. Mayers DL, Kohlbrenner VM, Dohnanyi C, et al. The inhibitory quotient (IQ) of tipranvir/ritonavir (TPV/r) in triple class experienced HIV+ patients: results from BI 1182.52 [abstract 9]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
30. Squires K, McCallister S, Lazzarin A, et al. Tipranavir/ritonavir (TPV/RTV) demonstrates a robust resistance profile in multiple protease inhibitor-experienced patients: correlation of baseline genotype and antiretroviral activity in BI 1182.52 [abstract 812]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.30.
31. Yeni P, MacGregor T, Gathe J, et al. Correlation of viral load reduction and plasma levels in multiple protease inhibitor (PI)-experienced patients taking tipranavir/ritonavir (TPV/r) in a phase IIB trial: BI 1182.52 [abstract 528]. In: Posters of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.31.
32. Hsu R, Wainberg M. Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing. J Acquir Immune Defic Syndr. 2004;35(Suppl 1):S13-S22.
33. Koh Y, Nakata H, Maeda K, et al. TMC114 (UIC96017): a novel nonpeptidic protease inhibitor potent against multi-PI resistant HIV in vitro [abstract 563]. In: Abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
34. Arasteh K, Clumeck N, Pozniak A, et al. First clinical results on antiretroviral activity, pharmacokinetics, and safety of TMC 114, an HIV-1 protease inhibitor, in multiple PI-experienced patients [abstract 8]. In: Posters of the 10th Conference on Retroviruses and Opportunistic Infections; Boston, February 10-14, 2003.
35. Johnson M, Nieto-Cisneros L, Horban A, et al. Roche Viracept (nelfinavir) 625 mg film-coated tablets: investigation of safety and gastrointestinal tolerability of this new formulation in comparison with 250 mg film-coated tablets (Viracept) in HIV patients [abstract 548]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.
36. Sterling TR, Vlahov D, Astemborski J, et al. Initial plasma HIV-1 RNA levels and progression to AIDS in women and men. N Engl J Med. 2001;344(10):720-725.
37. Swindells S, Cobos DG, Lee N, et al. Racial/ethnic differences in CD4 T cell count and viral load at presentation for medical care and in follow-up after HIV-1 infection. AIDS. 2002;16(13):1832-1834.
38. Agarwala S, Grasela D, Child M, et al. Characterization of the steady-state pharmacokinetic (PK) profile of atazanavir (ATV) beyond the 24-hour dosing interval [abstract 845]. In: Abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment; Paris, July 13-16, 2003.